Premium
Prognostic value of dual‐time‐point 18 F‐fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis
Author(s) -
UMEDA YUKIHIRO,
DEMURA YOSHIKI,
MORIKAWA MIWA,
AMESHIMA SHINGO,
TSUCHIDA TATSURO,
FUJIBAYASHI YASUHISA,
OKAZAWA HIDEHIKO,
ISHIZAKI TAKESHI
Publication year - 2011
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/j.1440-1843.2011.01966.x
Subject(s) - medicine , standardized uptake value , sarcoidosis , positron emission tomography , pulmonary sarcoidosis , nuclear medicine , lung , fluorodeoxyglucose
Background and objective: The value of dual‐time‐ point 18 F‐FDG PET was investigated to predict the prognosis of patients with pulmonary sarcoidosis. Methods: Twenty‐one patients with pulmonary sarcoidosis underwent 18 F‐FDG PET examinations at two time points: an early scan at 60 min and a delayed scan at 180 min after injection of 18 F‐FDG. Standardized uptake values (SUVs) at the two time points and the retention index (RI‐SUV) calculated from these were evaluated. To evaluate disease progression, all patients underwent chest CT 1 year after 18 F‐FDG PET. Using these results, the accuracy of 18 F‐FDG PET parameters and 67 Ga uptake for predicting disease persistence were compared, and the correlations between those parameters and serum markers were assessed. Results: RI‐SUV was significantly higher in patients with increased or unchanged pulmonary lesions at follow‐up CT (persistent group; 21.3 ± 9.6%) than in patients with improved pulmonary lesions (improved group; −9.2 ± 28.6%, P = 0.0075). The diagnostic accuracy of RI‐SUV in the persistent group was significantly greater than that of early SUV or 67 Ga uptake, and serum soluble IL‐2 receptor showed a significant correlation with RI‐SUV. Conclusions: RI‐SUV showed better diagnostic accuracy compared with early SUV or 67 Ga uptake, in patients with persistent lung involvement at 1 year. It may be a useful measure of persistent inflammation in patients with pulmonary sarcoidosis.